Featured Research

from universities, journals, and other organizations

New Approach To Treating Heart Attacks Reduces Risk Of Life-threatening Complications

Date:
June 25, 2009
Source:
St. Michael's Hospital
Summary:
Transferring heart attack patients to specialized hospitals to undergo angioplasty within six hours after receiving clot-busting drugs reduces the risk of life-threatening complications including repeat heart attacks, according to a new study.

Transferring heart attack patients to specialized hospitals to undergo angioplasty within six hours after receiving clot-busting drugs reduces the risk of life-threatening complications including repeat heart attacks, according to a new study from St. Michael's Hospital and Southlake Regional Hospital.

The findings, published June 22 in the New England Journal of Medicine, suggest that routine early transfer of patients after clot-busting drugs are administered results in significantly better outcomes than the current traditional practice of transferring patients only when the clot-busting drugs fail.

The study –which is the largest randomized trial of its kind to date -- followed 1,059 heart attack patients who were treated with clot-busting drugs at community hospital emergency departments in Ontario, Manitoba and Quebec. Researchers compared a strategy of transferring heart attack patients to hospitals with on-site angioplasty facilities to undergo angioplasty within six hours after administration of clot-busting drugs, as opposed to the traditional approach of transferring only those patients when clot-busting drug treatments are unsuccessful.

"When treating patients with heart attacks, timing is everything, " said Dr. Shaun Goodman, the study's chairman and associate head of cardiology at St. Michael's Hospital, "A patient's chances of recovery are significantly improved if care is provided in a setting where angioplasty can be done soon after clot-busting therapy is given."

All patients in the study initially sought treatment at a hospital without angioplasty capability and were treated with a newer clot-busting drug (tenecteplase). Patients were then randomly assigned to one of two groups: urgent transfer for angioplasty within six hours, or standard care (no transfer for angioplasty within the first 24 hours unless the clot-busting medication failed to restore blood flow in the blocked artery). Patients who received standard care often underwent angioplasty 24-72 hours after the heart attack.

Overall the research showed:

  • 17 per cent of patients receiving standard care had serious cardiac complications within 30 days, compared with 11 per cent of those transferred immediately for angioplasty. That represents a 36 per cent reduction in potentially life-threatening complications, including repeat heart attacks, with no difference in major bleeding complications between the two groups.
  • Patients who received the earlier angioplasty had lower rates of experiening chest pain (0.2 per cent as compared to 2.1 percent)
  • These same patients had fewer episodes of second heart attacks (3.4 per cent v 5.7 per cent)

Angioplasty – which uses a combination of catheter-mounted balloons and stents to open a completely blocked coronary artery and restore blood flow to the heart – is accepted as the best initial treatment for heart attacks when performed within 90 minutes of arrival at a hospital.

"The challenge, though, is that this is a goal that few hospitals in the world can achieve unless they have angioplasty facilities on site," explained the study's primary author Dr. Warren Cantor of Southlake Regional Health Centre, adding that less than 25 per cent of hospitals in North America have these resources. Until now, physicians have been reluctant to transfer patients to another hospital to undergo angioplasty soon after administering clot-busting medication as a result of earlier studies that revealed excess bleeding and no benefit with this approach.


Story Source:

The above story is based on materials provided by St. Michael's Hospital. Note: Materials may be edited for content and length.


Cite This Page:

St. Michael's Hospital. "New Approach To Treating Heart Attacks Reduces Risk Of Life-threatening Complications." ScienceDaily. ScienceDaily, 25 June 2009. <www.sciencedaily.com/releases/2009/06/090624193506.htm>.
St. Michael's Hospital. (2009, June 25). New Approach To Treating Heart Attacks Reduces Risk Of Life-threatening Complications. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/06/090624193506.htm
St. Michael's Hospital. "New Approach To Treating Heart Attacks Reduces Risk Of Life-threatening Complications." ScienceDaily. www.sciencedaily.com/releases/2009/06/090624193506.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins